BR0016172A - 4-piridinil-n-acil-l-fenilalaninas - Google Patents

4-piridinil-n-acil-l-fenilalaninas

Info

Publication number
BR0016172A
BR0016172A BR0016172-1A BR0016172A BR0016172A BR 0016172 A BR0016172 A BR 0016172A BR 0016172 A BR0016172 A BR 0016172A BR 0016172 A BR0016172 A BR 0016172A
Authority
BR
Brazil
Prior art keywords
pyridinyl
acyl
phenylalanines
vcam
binding
Prior art date
Application number
BR0016172-1A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BR0016172A publication Critical patent/BR0016172A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"4-PIRIDINIL-N-ACIL-L-FENILALANINAS". Compostos apresentando a fórmula (1) são revelados em que R~ 1~ a R~ 7~ são tal com definidos no presente documento e os quais tem atividade como inibidores de ligação entre VCAM-1 e células que expressam VLA-4 e, portanto, são úteis no tratamento de doenças cujos sintomas e/ou danos estão relacionados à ligação de VCAM-1 às células que expressam VLA-4, tal como doenças inflamatórias crónicas.
BR0016172-1A 1999-12-06 2000-11-29 4-piridinil-n-acil-l-fenilalaninas BR0016172A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16909099P 1999-12-06 1999-12-06
PCT/EP2000/011979 WO2001042215A1 (en) 1999-12-06 2000-11-29 4-pyridinyl-n-acyl-l-phenylalanines

Publications (1)

Publication Number Publication Date
BR0016172A true BR0016172A (pt) 2002-08-20

Family

ID=22614226

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0016172-1A BR0016172A (pt) 1999-12-06 2000-11-29 4-piridinil-n-acil-l-fenilalaninas

Country Status (34)

Country Link
EP (1) EP1244625B1 (pt)
JP (2) JP2003516392A (pt)
KR (1) KR100492111B1 (pt)
CN (1) CN1196682C (pt)
AR (1) AR031083A1 (pt)
AT (1) ATE297895T1 (pt)
AU (1) AU779063B2 (pt)
BR (1) BR0016172A (pt)
CA (1) CA2392566A1 (pt)
CO (1) CO5080771A1 (pt)
CZ (1) CZ20022352A3 (pt)
DE (1) DE60020883T2 (pt)
DK (1) DK1244625T3 (pt)
ES (1) ES2243335T3 (pt)
GC (1) GC0000214A (pt)
HK (1) HK1053470A1 (pt)
HR (1) HRP20020467A2 (pt)
HU (1) HUP0203735A3 (pt)
IL (2) IL149622A0 (pt)
JO (1) JO2281B1 (pt)
MA (1) MA26849A1 (pt)
MX (1) MXPA02005240A (pt)
MY (1) MY128003A (pt)
NO (1) NO322910B1 (pt)
NZ (1) NZ518888A (pt)
PE (1) PE20010960A1 (pt)
PL (1) PL364814A1 (pt)
PT (1) PT1244625E (pt)
RU (1) RU2270193C2 (pt)
TW (1) TWI276629B (pt)
UY (1) UY26470A1 (pt)
WO (1) WO2001042215A1 (pt)
YU (1) YU40502A (pt)
ZA (1) ZA200203762B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
KR100675036B1 (ko) 2000-08-18 2007-01-29 아지노모토 가부시키가이샤 신규한 페닐알라닌 유도체 및 이를 포함하는 의약품
DE60124573T2 (de) * 2000-09-29 2007-06-21 Ajinomoto Co., Inc. Neue phenylalanin-derivate
JP4452899B2 (ja) 2001-12-13 2010-04-21 味の素株式会社 新規フェニルアラニン誘導体
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
EP1465869B1 (en) 2001-12-21 2013-05-15 Exelixis Patent Company LLC Modulators of lxr
RU2390520C2 (ru) 2003-12-22 2010-05-27 Адзиномото Ко., Инк. Новые производные фенилаланина
US7618981B2 (en) * 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
JP4649476B2 (ja) * 2004-08-16 2011-03-09 メルク・シャープ・エンド・ドーム・コーポレイション Ｖｌａ−４拮抗薬
JP4784224B2 (ja) 2004-09-24 2011-10-05 味の素株式会社 糖鎖転移方法および糖鎖転移酵素
EP2007392A4 (en) * 2006-02-28 2010-04-07 Elan Pharm Inc METHOD FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES WITH ALPHA-4-INHIBITABLE COMPOUNDS
AR060901A1 (es) * 2006-05-12 2008-07-23 Jerini Ag Compuestos heterociclicos para la inhibicion de integrinas y uso de estos
CA2714335A1 (en) 2007-02-20 2008-08-28 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
AU2009234253C1 (en) 2008-04-11 2015-05-07 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
IN2012DN00638A (pt) * 2009-07-23 2015-08-21 Bayer Cropscience Ag
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
WO2013110680A1 (en) * 2012-01-27 2013-08-01 F. Hoffmann-La Roche Ag Integrin antagonist conjugates for targeted delivery to cells expressing vla-4
EP3008056B8 (en) * 2013-06-11 2021-03-03 Receptos Llc Novel glp-1 receptor modulators
PT3412660T (pt) 2016-02-05 2021-01-13 Ea Pharma Co Ltd Derivado de sulfonamida e composição farmacêutica contendo o mesmo
PE20211866A1 (es) 2018-10-30 2021-09-21 Gilead Sciences Inc Derivados de quinolina como inhibidores de la integrina alfa4beta7
US11174256B2 (en) 2018-10-30 2021-11-16 Gilead Sciences, Inc. Imidazopyridine derivatives
WO2020092401A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN
EP3873897B1 (en) 2018-10-30 2024-08-14 Gilead Sciences, Inc. N-benzoyl-phenylalanine derivatives as alpha4beta7 integrin inhibitors for treating inflammatory diseases
WO2021030438A1 (en) 2019-08-14 2021-02-18 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998053817A1 (en) * 1997-05-29 1998-12-03 Merck & Co., Inc. Biarylalkanoic acids as cell adhesion inhibitors
EP1001764A4 (en) * 1997-05-29 2005-08-24 Merck & Co Inc Heterocyclic amides as cell adhesion inhibitors
US6197794B1 (en) * 1998-01-08 2001-03-06 Celltech Therapeutics Limited Phenylalanine derivatives
MY153569A (en) * 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
US6329372B1 (en) * 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
JP2002504534A (ja) * 1998-02-26 2002-02-12 セルテック・セラピューティクス・リミテッド α４インテグリンの阻害剤としてのフェニルアラニン誘導体
GB9811159D0 (en) * 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds
EP1144365B1 (en) * 1998-12-22 2004-03-17 Tanabe Seiyaku Co., Ltd. Inhibitors of alpha-4 beta-1 mediated cell adhesion
ATE299490T1 (de) * 1999-01-22 2005-07-15 Elan Pharm Inc Multizyklische verbindungen zur hemmung der durch vla-4 vermittelten leukozytenadhäsion

Also Published As

Publication number Publication date
KR20020060256A (ko) 2002-07-16
GC0000214A (en) 2006-03-29
TWI276629B (en) 2007-03-21
WO2001042215A1 (en) 2001-06-14
HRP20020467A2 (en) 2004-04-30
PL364814A1 (en) 2004-12-13
EP1244625A1 (en) 2002-10-02
MXPA02005240A (es) 2002-11-07
EP1244625B1 (en) 2005-06-15
PE20010960A1 (es) 2001-09-22
DK1244625T3 (da) 2005-10-10
HUP0203735A3 (en) 2005-03-29
CN1196682C (zh) 2005-04-13
DE60020883T2 (de) 2006-03-23
CO5080771A1 (es) 2001-09-25
ZA200203762B (en) 2004-01-28
NZ518888A (en) 2004-02-27
NO20022650L (no) 2002-06-05
ES2243335T3 (es) 2005-12-01
PT1244625E (pt) 2005-09-30
NO20022650D0 (no) 2002-06-05
KR100492111B1 (ko) 2005-06-01
HUP0203735A2 (hu) 2003-03-28
AU2163901A (en) 2001-06-18
JP2008094842A (ja) 2008-04-24
JO2281B1 (en) 2005-09-12
JP2003516392A (ja) 2003-05-13
NO322910B1 (no) 2006-12-18
UY26470A1 (es) 2001-05-31
AU779063B2 (en) 2005-01-06
CN1402709A (zh) 2003-03-12
RU2270193C2 (ru) 2006-02-20
ATE297895T1 (de) 2005-07-15
YU40502A (sh) 2005-03-15
DE60020883D1 (de) 2005-07-21
AR031083A1 (es) 2003-09-10
MY128003A (en) 2007-01-31
HK1053470A1 (en) 2003-10-24
CA2392566A1 (en) 2001-06-14
MA26849A1 (fr) 2004-12-20
IL149622A (en) 2006-12-10
IL149622A0 (en) 2002-11-10
CZ20022352A3 (cs) 2003-05-14

Similar Documents

Publication Publication Date Title
BR0016172A (pt) 4-piridinil-n-acil-l-fenilalaninas
BR0016195A (pt) 4-pirimidinil-n-acil-l-fenilalaninas
DE69824183T2 (de) N-alkanoylphenylalaninderivate
BR9811988A (pt) Derivados de n-alcanoilfenilalanina
BR0009167A (pt) Inibidores de enzima impdh
BR0111206A (pt) Derivados de arilmetilamina para uso como inibidores de triptase
BR0010076A (pt) Inibidores de renina
BRPI0517999A (pt) derivados de tetraidropirano como antidiabéticos
BR0010080A (pt) Inibidores de renina
BR0007527A (pt) Fenilfenantridinas com atividade inibitória depde-iv
IT1303249B1 (it) Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
BR9810450A (pt) Derivados de ácido barbitúrico com atividade antimetastática e antitumor
BR0011291A (pt) Derivados de ácido hidroxâmico como inibidores de metaloprotease de matriz
NO20014240D0 (no) C16-umettede FP-selektive prostaglandinanaloger
BRPI0511323A (pt) tetraidroisoquinolinas substituìdas usadas na forma de inibidores de mmp, método para a produção e uso das mesmas na forma de drágeas
TR200103004T2 (tr) Pirolidinkarbonilamino siklik disülfitler.
BR0008368A (pt) Derivados fenilalaninol
BR0015404A (pt) Compostos relacionados com ácido 15-hidroxieicosatetraenóico e métodos de uso
DK1244643T3 (da) Tryptaseinhibitorer
DK1244614T3 (da) Tryptase-inhibitorer
SE0301885D0 (sv) New use IV
BRPI0417140A (pt) derivados quinolina ácidos e seu uso na prevenção e/ou tratamento de patologias relacionadas com hiperglicemia
ATE348803T1 (de) Tryptase-inhibitoren
ECSP982634A (es) Derivados de n- aroilofenil alanina

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8, 10(VIII), 11, 13, 24 E 25 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.